Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's Disease

ASSERT Study Shows Increased Transport of Amyloid Beta 40

CALGARY, Alberta, January 25, 2011 - Resverlogix announced today that its lead drug RVX-208, a first in class
ApoA-I production drug, illustrated positive effects on an important
cognitive function and Alzheimer's Disease (AD) marker, plasma Amyloid beta
40 (Abeta40). This analysis was performed based on increasing evidence in the
literature that the transport of potentially harmful Abeta40 from the brain
to the general circulatory system may be beneficial.

Several population studies have indicated that high HDL cholesterol is
associated with protection from developing Alzheimer's Disease. It has also
been shown that low plasma Abeta40 is a risk factor for developing
Alzheimer's Disease in older patients. Since the Alzheimer's Disease
biomarker Abeta40 bind to ApoA-I it has been hypothesized that increasing
ApoA-I would transport Abeta40 out of the brain thereby decreasing the
Abeta40 load in the brain, in effect having possible disease modifying
effect.

To assess potential for treatment effects by RVX-208 on Alzheimer's
Disease, plasma Abeta40 was analyzed before and after 12 weeks treatment in a
stable coronary artery disease population, i.e. the ASSERT population of 299
patients.

In the quartile with the lowest plasma Abeta40 at baseline, which is
known to be at greater risk for developing Alzheimer's Disease, at a dose of
150 mg, b.i.d., a highly significant 34.8 pg/mL change from baseline
(p=0.0013) and 13.4% change compared to placebo was observed. The data
further supports previous Phase I trial data and the hypothesis that RVX-208
treatment can also augment Abeta40 transport from the brain.

Dr. Jan Johansson Senior Vice President of Medical Affairs stated, "We
have been building upon a hypothesis that increased Abeta40 seen in plasma
illustrates movement out of the brain. We believe the augmented ApoA-I
production by RVX-208, functional HDL and enhanced reverse cholesterol
transport, could be transporting potentially harmful Abeta40 from the brain
to plasma. This is a very important new area of neurovascular biology that we
intend to pursue."

"These repeated findings will help continue to drive our efforts to
further understand the complex relationship between lipoproteins, amyloid
beta and the devastating disease of Alzheimer's. Further analysis and
planning will take place prior to determining the next steps, however, as
this drug has already passed Phase I, of the FDA review process, a future
trial would likely commence as a Phase II program in Alzheimer's Disease
patients," added Dr. Johansson.

Emerging evidence and data is accumulating for a protective effect of
good HDL cholesterol against Alzheimer's Disease. Key findings from large
epidemiology studies such as the Harvard Women's Study, the Honolulu Aging
Study, the White Hall 2 study and the Manhattan Cognitive Study continue to
build the relationship between increased HDL, ApoA-I and improved cognitive
function and Alzheimer's outcomes.

About RVX-208

RVX-208, a novel small molecule therapeutic that facilitates endogenous
ApoA-I production, is positioned to be one of the most promising emerging
drugs in the treatment of atherosclerosis. Apolipoprotein A-I (ApoA-I), the
main component of high-density lipoprotein (HDL) represent the body's natural
defense system against atherosclerosis by mediating reverse cholesterol
transport, i.e. transport of peripheral cholesterol including that of the
vessel wall to the liver for processing. Analysis of cognitive biomarkers
such as Amyloid Beta 40 (Abeta40) in conjunction with lipid transport markers
may also provide new research and development opportunities for RVX-208 in
important disease areas such as Alzheimer's Disease. To the Company's
knowledge RVX-208 is the only novel small molecule that is specifically
designed to increase ApoA-I production and thereby raise HDL levels thus
enhancing HDL functionality to augment reverse cholesterol transport (RCT)
and Abeta40 transport.

RCT is a pathway by which accumulated cholesterol is transported from the
arterial wall to the liver for excretion, thus preventing atherosclerosis.
Major constituents of RCT include acceptors such as HDL and ApoA-I. A
critical part of RCT is cholesterol efflux, in which accumulated cholesterol
is removed from macrophages.

The American Heart Association estimates that almost 80 million American
Adults have one or more types of cardiovascular disease. CVD remains the
number one killer of developed nations. Nearly 2400 Americans die each day
from cardiovascular disease.

About ASSERT Trial

The ASSERT study evaluated early biochemical changes in association with
increasing doses of an apoA-I inducer (RVX-208 100-300 mg daily) for 12 weeks
in statin-treated patients with stable coronary artery disease.

About Vascular Dementia Multi-infarct dementia, also known as vascular
dementia, is the second most common form of dementia after Alzheimer's
Disease in older adults. Early detection and accurate diagnosis are
important, as vascular dementia is at least partially preventable. Vascular
dementia is the second most common cause of dementia in the United States and
Europe in the elderly, but it is the most common form in some parts of Asia.
The prevalence of the illness is 1.5% in Western countries and approximately
2.2% in Japan. It accounts for 50% of all dementias in Japan, 20% to 40% in
Europe and 15% in Latin America. The incidence of dementia is 9 times higher
in patients who have had a stroke than in controls. 25% of stroke patients
develop new-onset dementia within 1 year of their stroke. The relative risk
of incident dementia is 5.5% within 4 years of suffering a stroke.

About Alzheimer's Disease

Every 71 seconds, someone in America develops Alzheimer's Disease and it
is estimated that by mid-century, someone will develop Alzheimer's every 33
seconds. Neurodegenerative diseases such as Alzheimer's are one of the most
debilitating in the developed world with an estimated prevalence in the
United States alone to grow to 15 million people by 2050. In a report
commissioned by the Alzheimer's Association, caregiver costs in the United
States are estimated at US$36.5 billion which includes loss of productivity,
absenteeism and worker replacement. In addition it is also estimated that
one-half to two-thirds of the cost of AD care stems from unpaid caregivers
(often family members), who spend 16-35 hours per week looking after a person
with AD. These figures underscore the importance of developing new therapies
to aide in the socioeconomic burden of AD.

About Resverlogix Corp.

Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet medical needs. The NexVas(TM) PR program is the Company's
primary focus to develop novel small molecules that enhance ApoA-I. These
vital therapies address the burden of atherosclerosis and other important
diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease,
Peripheral Artery Disease and other vascular disorders. Resverlogix Corp.'s
common shares trade on the Toronto Stock Exchange (TSX:RVX). For further
information please visit www.resverlogix.com.

This news release may contain certain forward-looking statements as
defined under applicable Canadian securities legislation, including our
statements with respect to research, development and commercialization of
novel therapeutics that reduce the risk of cardiovascular disease including
atherosclerosis, diabetes, Alzheimer's disease, Peripheral Artery Disease and
other vascular diseases. These forward-looking statements contained herein
that are not based on historical fact, including without limitation
statements containing the words "believes", "anticipates", "plans",
"intends", "will", "should", "expects", "continue", "estimate", "forecasts"
and other similar expressions. Our actual results, events or developments
could be materially different from those expressed or implied by these
forward-looking statements. We can give no assurance that any of the events
or expectations will occur or be realized. By their nature, forward-looking
statements are subject to numerous known and unknown risks and uncertainties
including but not limited to those associated with the success of research
and development programs, clinical trial programs including possible delays
in patient recruitment, the regulatory approval process, competition,
securing and maintaining corporate alliances, market acceptance of the
Company's products, the availability of government and insurance
reimbursements for the Company's products, the strength of intellectual
property, financing capability, the potential dilutive effects of any
financing, reliance on subcontractors and key personnel and additional risk
factors discussed in other documents we file from time to time with
securities authorities, which are available through SEDAR at
www.sedar.com. Additionally, risks and uncertainties are discussed in
detail in the October 31, 2010 MD&A. The forward-looking statements contained
in this news release are expressly qualified by this cautionary statement are
made as of the date hereof. The Company disclaims any intention and has no
obligation or responsibility, except as required by law, to update or revise
any forward-looking statements, whether as a result of new information,
future events or otherwise. The TSX Exchange does not accept responsibility
for the adequacy or accuracy of this news release.

%SEDAR: 00019253E

For further information:

    Kenneth E. Lebioda
    Senior Vice President
    Resverlogix Corp.
    Phone: +1-403-254-9252
    Email: Ken@resverlogix.com

    US Institutional Investors
    Susan Noonan
    Managing Partner
    S.A. Noonan Communications, LLC
    Phone: +1-212-966-3650
    Email: Susan@sanoonan.com

Website: www.resverlogix.com

Kenneth E. Lebioda, Senior Vice President, Resverlogix Corp., Phone: +1-403-254-9252, Email: Ken at resverlogix.com; US Institutional Investors, Susan Noonan, Managing Partner, S.A. Noonan Communications, LLC, Phone: +1-212-966-3650, Email: Susan at sanoonan.com